Eli Lilly CEO's Total Compensation Rose 10% in 2024

Dow Jones
08 Mar

By Connor Hart

Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier.

Ricks' payout included $19.7 million in stock awards, $5.7 million in bonuses and nearly $352,000 in other forms of compensation, according to the drugmaker's 2025 proxy statement filed Friday with the Securities and Exchange Commission. His base salary for the year was $1.7 million.

Bonuses were tied to performance. Eli Lilly said that executives' performance highlights last year included delivering a strong financial performance, with product revenue and earnings per share topping internal targets, as well as furthering its pipeline of treatments.

Lucas Montarce, who was appointed as Eli Lilly's top finance chief in September, received $2.9 million in total compensation in 2024.

Montarce succeeded Anat Ashkenazi, who left the company earlier in the year to become CFO of Google-parent Alphabet. For her work with Eli Lilly in 2024, Ashkenazi received $5 million in total compensation.

Gordon Brooks, who served as interim CFO for a period in 2024, as well as group vice president of corporate strategy and controller, notched $2.7 million in total compensation for the year.

Other executive payouts in 2024 included Chief Scientific Officer Daniel Skovronsky, who received $12.6 million; General Counsel and Secretary Anat Hakim, who received $7.5 million; and President of Loxo@Lilly Jake Van Naarden, who received $5.8 million.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

March 07, 2025 17:15 ET (22:15 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10